Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib and Atezolizumab in Advanced Solid Tumors
NCT04276376Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Apr 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rucaparib and atezolizumab in non-small cell lung cancer (NSCLC), Urothelial Bladder Cancer (UBC), prostate cancer (PCa) and 3 more (4 arms), sponsored by Gustave Roussy. Primary endpoint: Overall Response Rate at 12 weeks. Started Apr 2019; status: terminated.
02
Drugs
rucaparibatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)Urothelial Bladder Cancer (UBC)prostate cancer (PCa)gastric adenocarcinomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04276376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276376.